PMID- 30276203
OWN - NLM
STAT- MEDLINE
DCOM- 20190110
LR  - 20190110
IS  - 2314-6141 (Electronic)
IS  - 2314-6133 (Print)
VI  - 2018
DP  - 2018
TI  - Microarray-Based Detection and Clinical Evaluation for Helicobacter pylori 
      Resistance to Clarithromycin or Levofloxacin and the Genotype of CYP2C19 in 1083 
      Patients.
PG  - 2684836
LID - 10.1155/2018/2684836 [doi]
LID - 2684836
AB  - Background. Helicobacter pylori (H. pylori) is one of the most frequent and 
      persistent bacterial infections that affect nearly half of the world's 
      population. Antibiotic resistance is a constantly evolving process and local 
      surveillance of antibiotic resistance is warranted to guide clinicians in their 
      choice of therapy. The aim of this study was to establish a microarray-based 
      detection to identify H. pylori infection, clarithromycin and levofloxacin 
      susceptibility, and CYP2C19 genetic polymorphism and guide to potential choice of 
      proton pump inhibitor (PPI), antibiotic administration for tailored H. pylori 
      eradication therapy. Methods. By analyzing the sequence of human genomic 
      CYP2C19⁎2 and CYP2C19⁎3 and mutations within the 23S rRNA and gyrA gene regions 
      conferring clarithromycin and levofloxacin resistance, respectively, we developed 
      a microarray for individual therapy detection of H. pylori infection. Plasmids 
      were established as positive or limit of detection (LOD) reference materials. The 
      specificity and sensitivity of the microarray had been performed. And a total of 
      1083 gastric biopsy samples were tested and the Kappa value had been calculated 
      between the array and Sanger sequencing. We also analyzed the resistance to 
      clarithromycin and levofloxacin in China, as well as the CYP2C19 polymorphisms. 
      Results. The LOD of detecting H. pylori was 10(3) CFU/mL and human genome DNA was 
      2 ng/muL. The detection results of 1083 gastric biopsy samples showed that 691 
      (63.80%) were H. pylori positive, of which 266 (38.49%) were resistant to 
      clarithromycin, 192 (27.79%) were resistant to levofloxacin, and 61 (8.83%) were 
      resistant to both of them. For the type of CYP2C19 polymorphism, 412 (38.04%) 
      were homozygous fast type (HomEM), 574 (53%) were heterozygous EM (HetEM), and 97 
      (8.96%) were poor metabolizer (PM). Conclusions. The proposed microarray-based 
      detection has high specificity, sensitivity, and reproducibility for detecting 
      the resistance of clarithromycin or levofloxacin as well as CYP2C19 polymorphism, 
      which may help to improve the clinical eradication rate of H. pylori.
FAU - Song, Yi
AU  - Song Y
AUID- ORCID: 0000-0001-5240-462X
AD  - Beijing Institute of Radiation Medicine, Beijing, China.
AD  - Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious 
      Diseases, Beijing, China.
FAU - Dou, Fengna
AU  - Dou F
AD  - Beijing Institute of Radiation Medicine, Beijing, China.
AD  - Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious 
      Diseases, Beijing, China.
FAU - Zhou, Zhe
AU  - Zhou Z
AD  - Beijing Institute of Radiation Medicine, Beijing, China.
AD  - Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious 
      Diseases, Beijing, China.
FAU - Yang, Ningmin
AU  - Yang N
AD  - Hangzhou Zhiyuan Medical Laboratory Co., Ltd., Hangzhou, China.
FAU - Zhong, Jing
AU  - Zhong J
AD  - Huzhou Central Hospital, Huzhou, China.
FAU - Pan, Jie
AU  - Pan J
AD  - Wenzhou Central Hospital, Wenzhou, China.
FAU - Liu, Qiqi
AU  - Liu Q
AUID- ORCID: 0000-0002-1534-0919
AD  - Beijing Institute of Radiation Medicine, Beijing, China.
AD  - Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious 
      Diseases, Beijing, China.
FAU - Zhang, Jianzhong
AU  - Zhang J
AUID- ORCID: 0000-0001-7056-8206
AD  - State Key Laboratory of Infectious Disease Prevention and Control, Collaborative 
      Innovation Center for Diagnosis and Treatment of Infectious Diseases, Chinese 
      Center for Disease Control and Prevention, Beijing, China.
FAU - Wang, Shengqi
AU  - Wang S
AUID- ORCID: 0000-0001-8100-7295
AD  - Beijing Institute of Radiation Medicine, Beijing, China.
AD  - Beijing Key Laboratory of New Molecular Diagnosis Technologies for Infectious 
      Diseases, Beijing, China.
LA  - eng
PT  - Journal Article
DEP - 20180910
PL  - United States
TA  - Biomed Res Int
JT  - BioMed research international
JID - 101600173
RN  - 0 (Anti-Bacterial Agents)
RN  - 6GNT3Y5LMF (Levofloxacin)
RN  - 804826J2HU (Amoxicillin)
RN  - EC 1.14.14.1 (CYP2C19 protein, human)
RN  - EC 1.14.14.1 (Cytochrome P-450 CYP2C19)
RN  - H1250JIK0A (Clarithromycin)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amoxicillin
MH  - Anti-Bacterial Agents/*pharmacology
MH  - China
MH  - Clarithromycin/*pharmacology
MH  - Cytochrome P-450 CYP2C19/drug effects/*genetics/metabolism
MH  - Drug Resistance, Bacterial
MH  - Female
MH  - Genotype
MH  - Germany
MH  - Helicobacter Infections/drug therapy
MH  - Helicobacter pylori/*drug effects/genetics
MH  - Humans
MH  - Levofloxacin/*pharmacology
MH  - Male
MH  - Middle Aged
MH  - Reproducibility of Results
MH  - Young Adult
PMC - PMC6151853
EDAT- 2018/10/03 06:00
MHDA- 2019/01/11 06:00
PMCR- 2018/09/10
CRDT- 2018/10/03 06:00
PHST- 2018/05/01 00:00 [received]
PHST- 2018/07/24 00:00 [revised]
PHST- 2018/08/08 00:00 [accepted]
PHST- 2018/10/03 06:00 [entrez]
PHST- 2018/10/03 06:00 [pubmed]
PHST- 2019/01/11 06:00 [medline]
PHST- 2018/09/10 00:00 [pmc-release]
AID - 10.1155/2018/2684836 [doi]
PST - epublish
SO  - Biomed Res Int. 2018 Sep 10;2018:2684836. doi: 10.1155/2018/2684836. eCollection 
      2018.